• Title/Summary/Keyword: Bio Venture

Search Result 162, Processing Time 0.037 seconds

Case Study on the Effect of IPO on the Technology Commercialization Performance of the New Drug Development Bio Venture Company (증권시장 상장이 신약개발 바이오벤처기업의 기술사업화 성과에 미치는 사례연구)

  • Kim, Ju Young;Ha, Kyu Soo
    • Asia-Pacific Journal of Business Venturing and Entrepreneurship
    • /
    • v.14 no.1
    • /
    • pp.151-166
    • /
    • 2019

  • New drug development requires 10 to 15 years of long time and more than $ 1 billion in funding, ranging from basic research${\rightarrow}$preclinical medicine${\rightarrow}$clinical medicine${\rightarrow}$product approval${\rightarrow}$sales. Many new drug development bio-venture companies will continue to pursue new drug development with funds secured through listing on the securities market. This study focuses on the impact of the listing on the market of bio-venture companies in the development of new drugs. It is necessary to determine whether the increase in registered patent, preclinical, clinical and technology transfer contracts at the time of listing (D) The results of this study are as follows. We also analyzed whether the registered patent, preclinical, and clinical effects had significant effect on technology transfer contracts at two years after listing and listing. The results of the analysis are as follows. First, Korea's new drug development bio-venture firms increased their registered patents but did not increase their pre-clinical, clinical and technology transfer contracts. Second, at the time of listing and two years after listing, pre-employment has a significant effect on Korea's technology transfer contracts and has a significant effect on overseas technology transfer contracts. However, registered patents and clinics have significant influence on technology transfer contracts. Korea 's new drug development bio-venture firms showed patent increase despite the stock market listing, but pre-clinical, clinical and technology transfer contracts did not increase. In order to strengthen technological commercialization of new drug development bio-venture companies in the future, it is required to establish R & D strategy for efficient use of IPO subscription funds, open innovation through strengthening industry-academia-partnerships, and more sophisticated preclinical and clinical strategy establishment.

  • PDF KSCI

기술아웃소싱 계약 이것만은 챙겨두자

  • 정다운
    • Bio news
    • /
    • no.5
    • /
    • pp.6-7
    • /
    • 2004

  • 2000년도를 기점으로 바이오 붐을 타고 많은 신약 및 바이오 관련 기업들이 설립되었고 이에 4년여의 시간이 경과되었다. 초기 바이오벤처는 국책과제, 투자유치 등을 통해 기반 연구를 수행하였으나, 현재는 기업 생존을 위해 지금까지 수행된 연구결과를 사업화하고 수익을 창출하기 위한 다각적인 노력을 기울이고 있는 시점이다. 많은 바이오 벤처들은 궁극적으로 맞춤의약시대에 걸맞은 신약개발, 장기이식, 유전자치료 등의 목표를 설정해 두고 있다. 그러나 이러한 목

  • PDF